KR910011279A - 스테로이드 요법에 의한 부작용을 경감 또는 예방방법 및 이를 위한 조성물 - Google Patents
스테로이드 요법에 의한 부작용을 경감 또는 예방방법 및 이를 위한 조성물 Download PDFInfo
- Publication number
- KR910011279A KR910011279A KR1019900021111A KR900021111A KR910011279A KR 910011279 A KR910011279 A KR 910011279A KR 1019900021111 A KR1019900021111 A KR 1019900021111A KR 900021111 A KR900021111 A KR 900021111A KR 910011279 A KR910011279 A KR 910011279A
- Authority
- KR
- South Korea
- Prior art keywords
- corticosteroid
- igf
- activity
- steroid
- administration
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract 19
- 238000000034 method Methods 0.000 title claims abstract 14
- 150000003431 steroids Chemical class 0.000 title claims abstract 13
- 239000000203 mixture Substances 0.000 title claims abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title claims 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract 12
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract 12
- 239000003246 corticosteroid Substances 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002011 fludrocortisone Drugs 0.000 claims 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 1
- 229960000618 fluprednisolone Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 meprednison Chemical compound 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000012261 overproduction Methods 0.000 claims 1
- 229960002858 paramethasone Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037314 wound repair Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (16)
- 코르티코스테로이드 활성을 갖는 스테로이드의 투여가 필용하거나 이러한 스테로이드가 내인성-과다생성되는 포유동물에 IGF-I 또는 이의 활성 단면 또는 동족체를 코르디코스테로이드의 부작용을 경감시키거나 예방하는데 유효한 량으로 투여함을 특징으로 하여, 언급된 포유동물에게서 코르티코스테로이드 활성의 부작용을 경감시키거나 예방하는 방법.
- 제1항에 있어서, 코르티코스테로이드 부작용이 코르티코스테로이드 부작용이 코르티코스테로이드 활성을 갖는 외인성 스테로이드의 투여결과인 방법.
- 제1항에 있어서, 코르티코스테로이드 부작용이 코르티코스테로이드 활성을 갖는 스테로이드의 내인성 과다 생성의 결과인 방법.
- 제2항에 있어서, 코르티코스테로이드 부작용이 코르티코스테로이드 활성을 갖는 외인성 스테로이드의 만성 투여의 결과인 방법.
- 제2항에 있어서, 외인성 스테로이드가 베클로 메타손, 베타메타손, 코르티손, 테스옥시코프티코스테론, 텍사메타손, 플루드로코르티손, 플루프레드니솔론, 하이드로코르티손, 메프레드니손, 메틸프레드니솔론, 파라메타손, 프레드니솔론, 프레드니손 및 트리암시놀론 중에서 선택되는 방법.
- 제1항에 있어서, 언급된 스테로이드 및 IGF-I 또는 이의 활성 단편 또는 동족체를 단일 제제로 투여하는 방법.
- 제1항에 있어서, 언급된 스테로이드 및 IGD-I를 별도의 제제로 투여하는 방법.
- 제7항에 있어서, 별도의 제제를 상이한 투여 경로를 통하여 투여하는 방법.
- 제7항에 있어서, 별도의 제제를 동일한 투여 경로를 통하여 투여하는 방법.
- 제2항에 있어서, 코르티코스테로이드 활성을 갖는 스테로이드가 골관절염의 치료에 두여된 방법.
- 제1항에 있어서, IGF-I 또는 이의 활성 단편이 치료 대상종의 IGF-I의 천연형에 상응하지 않는 방법.
- 제1항에 있어서, IGF-I 또는 이의 활성 단편이 치료 대상종의 IGF-I의 천연형에 상응하지 않는 방법.
- 제1항에 있어서, IGF-I 또는 이의 활성 단편 또는 동족체가 제조합 기술에 의해 제조되는 방법.
- 크로티코스테로이드 활성을 갖는 스테로이드와 함께 또는 이러한 스테로이드의 투여전후에, IGF-I 또는 이의 활성 단편 또는 동족체를, 코르티코스테로이드 요법의 안전화량으로, 크르티코스테로이드 요법이 필요한 포유동물에 투여함을 특징으로 하여, 언급된 포유동물에게서 코르티코스테로이드 요법을 안전하게 하는 방법.
- 약제학적으로 유효한 양의 코르티코스테로이드 활성을 갖는 스테로이드 및 코르티코스테로이드 부작용을 경감시키거나 예방하기에 유효한 양의 IGF-I 또는 이의 활성 단편 또는 동족체를 함유하는 코르티코스테로이드 치료 조성물.
- 코르티코스테로이드 활성을 갖는 스테로이드의 투여가 필요하거나 이러한 스테로이드가 내인성-과다생성 되는 포유동물에게서 코르티코스테로이드 활성의 부작용을 경감시키거나 예방하는 약제의 제조를 위한 IGF-I의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45521589A | 1989-12-22 | 1989-12-22 | |
| US455215 | 1989-12-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR910011279A true KR910011279A (ko) | 1991-08-07 |
| KR100191381B1 KR100191381B1 (ko) | 1999-06-15 |
Family
ID=23807878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019900021111A KR100191381B1 (ko) | 1989-12-22 | 1990-12-20 | 스테로이드 요법에 의한 부작용을 경감 또는 예방하고 코르티코스테로이드 요법을 안전화시키기 위한 조성물 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0434625B1 (ko) |
| JP (1) | JP2934023B2 (ko) |
| KR (1) | KR100191381B1 (ko) |
| AT (1) | ATE121296T1 (ko) |
| AU (1) | AU641966B2 (ko) |
| CA (1) | CA2032859C (ko) |
| DE (1) | DE69018799T2 (ko) |
| DK (1) | DK0434625T3 (ko) |
| ES (1) | ES2071080T3 (ko) |
| GR (1) | GR3015900T3 (ko) |
| IE (1) | IE67510B1 (ko) |
| IL (1) | IL96711A (ko) |
| NZ (1) | NZ236614A (ko) |
| ZA (1) | ZA9010332B (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128320A (en) * | 1990-01-18 | 1992-07-07 | Genentech, Inc. | Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i |
| TW267102B (ko) | 1992-03-13 | 1996-01-01 | Ciba Geigy | |
| US5407913A (en) * | 1992-12-03 | 1995-04-18 | Celtrix Pharmaceuticals, Inc. | Method and composition for systemic treatment of tissue injury |
| US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
| WO1996007744A1 (en) * | 1994-09-08 | 1996-03-14 | Chiron Corporation | A method of improved production of insulin-like growth factor |
| WO1997015319A1 (en) * | 1995-10-23 | 1997-05-01 | Queen's University At Kingston | Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1 |
| WO1998011913A1 (en) * | 1996-09-16 | 1998-03-26 | Dalhousie University | Use of igf-i for the treatment of polycystic kidney disease and related indications |
| US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| AU3548999A (en) | 1998-04-03 | 1999-10-25 | Chiron Corporation | Use of igfi for treating articular cartilage disorders |
| AU762351B2 (en) | 1999-01-06 | 2003-06-26 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
| WO2001087323A2 (en) | 2000-05-16 | 2001-11-22 | Genentech, Inc. | Method for treating cartilage disorders |
| EP1917039A4 (en) * | 2005-08-01 | 2011-01-19 | Genera Istrazivanja D O O | METHODS AND COMPOSITIONS FOR REGENERATING JOINT CARTILAGE |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0289584B1 (en) * | 1986-11-14 | 1993-05-05 | Institute of Molecular Biology, Inc. | Wound healing and bone regeneration |
| SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US4983581A (en) * | 1988-05-20 | 1991-01-08 | Institute Of Molecular Biology, Inc. | Wound healing composition of IGF-I and TGF-β |
-
1990
- 1990-12-12 ZA ZA9010332A patent/ZA9010332B/xx unknown
- 1990-12-13 ES ES90810987T patent/ES2071080T3/es not_active Expired - Lifetime
- 1990-12-13 DE DE69018799T patent/DE69018799T2/de not_active Expired - Fee Related
- 1990-12-13 AT AT90810987T patent/ATE121296T1/de not_active IP Right Cessation
- 1990-12-13 EP EP90810987A patent/EP0434625B1/en not_active Expired - Lifetime
- 1990-12-13 DK DK90810987.9T patent/DK0434625T3/da active
- 1990-12-18 IL IL9671190A patent/IL96711A/en not_active IP Right Cessation
- 1990-12-19 AU AU68247/90A patent/AU641966B2/en not_active Ceased
- 1990-12-20 CA CA002032859A patent/CA2032859C/en not_active Expired - Fee Related
- 1990-12-20 KR KR1019900021111A patent/KR100191381B1/ko not_active IP Right Cessation
- 1990-12-21 NZ NZ236614A patent/NZ236614A/xx unknown
- 1990-12-21 IE IE468490A patent/IE67510B1/en not_active IP Right Cessation
- 1990-12-21 JP JP2405132A patent/JP2934023B2/ja not_active Expired - Fee Related
-
1995
- 1995-04-20 GR GR950400745T patent/GR3015900T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69018799D1 (de) | 1995-05-24 |
| ATE121296T1 (de) | 1995-05-15 |
| AU641966B2 (en) | 1993-10-07 |
| IL96711A0 (en) | 1991-09-16 |
| EP0434625B1 (en) | 1995-04-19 |
| EP0434625A3 (en) | 1991-10-02 |
| EP0434625A2 (en) | 1991-06-26 |
| IE904684A1 (en) | 1991-07-17 |
| CA2032859A1 (en) | 1991-06-23 |
| AU6824790A (en) | 1991-06-27 |
| JP2934023B2 (ja) | 1999-08-16 |
| IE67510B1 (en) | 1996-04-03 |
| IL96711A (en) | 1996-01-19 |
| JPH04210648A (ja) | 1992-07-31 |
| CA2032859C (en) | 2007-09-17 |
| ES2071080T3 (es) | 1995-06-16 |
| DE69018799T2 (de) | 1995-09-21 |
| ZA9010332B (en) | 1991-08-28 |
| KR100191381B1 (ko) | 1999-06-15 |
| DK0434625T3 (da) | 1995-06-26 |
| GR3015900T3 (en) | 1995-07-31 |
| NZ236614A (en) | 1993-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910011279A (ko) | 스테로이드 요법에 의한 부작용을 경감 또는 예방방법 및 이를 위한 조성물 | |
| De Wied | Influence of anterior pituitary on avoidance learning and escape behavior | |
| Ehrlich et al. | Effects of cortisone and vitamin A on wound healing | |
| Watts et al. | Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause | |
| CN1100542C (zh) | 用于治疗irds和ards的含有至少一种糖皮质激素并混以一种肺表面活性剂的组合物 | |
| BRANSOME JR et al. | Studies of adrenal nucleic acids: the influence of ACTH, unilateral adrenalectomy and growth hormone upon adrenal RNA and DNA in the dog | |
| SUDA et al. | Effect of dexamethasone on immunoreactive corticotropin-releasing factor in the rat median eminence and intermediate-posterior pituitary | |
| Bhakoo et al. | Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma | |
| Kuntzman et al. | Effect of drugs and insecticides on the anesthetic action of steroids | |
| Wells et al. | Regulation by sympathetic nervous system of accelerated growth of salivary glands of rats | |
| US3966924A (en) | Composition and method for treating psoriasis | |
| Perry et al. | Effect of oxandrolone and timing of oral ethinylestradiol initiation on pubertal progression, height velocity and bone maturation in the UK Turner study | |
| Naveh et al. | Corticosteroid treatment of laser retinal damage affects prostaglandin E2 response. | |
| ATE122564T1 (de) | Kombinierung von tobramycin und steroiden für topische ophthalmische verwendung. | |
| GEMZELL et al. | Effect of androgens on plasma levels of 17-hydroxycorticosteroids | |
| US5358943A (en) | Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids | |
| Kraulis et al. | The effects of corticosterone, 18-OH-DOC, DOC and 11β-hydroxyprogesterone on the adrenal pituitary axis of the stressed rat | |
| Jones et al. | Structure‐activity relationship of various corticosteroids on the feedback control of corticotrophin secretion | |
| US5004736A (en) | Procedure for obtaining the preparation for the treatment of the disease psoriasis: drug for the treatment of psoriasis and its application | |
| Krauss | Response of serum haptoglobin to inflammation in adrenalectomized rat. | |
| Hasegawa et al. | Adrenal hypertrophy produced by 17α-esterified glucocorticoids in rat foetus | |
| Aicardi et al. | Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation | |
| Luttge et al. | Studies on the possible role of 2-OH-estradiol in the control of sexual behavior in female rats | |
| Jalava et al. | Triamcinolone hexacetonide in the treatment of therapy-refractory gonitis | |
| Biswas et al. | EFFECT OF CORTICOSTERONE ON SERUM CONCENTRATIONS OF α2u-GLOBULIN AND ON SPERMATOGENESIS IN OESTROGEN-TREATED RATS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20080107 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |